This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular Intervention  • Thrombolysis  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 92 words of the full text and any section headings.

In Reply: We appreciate the comments by Dr Arbit, although we disagree with his position that the ratio of anti-factor Xa–anti-factor IIa activity of heparins is meaningless. This ratio is a reflection of polysaccharide chain length distribution, and this distribution affects the rate of heparin clearance and potentially the width of the therapeutic window. Our editorial was focused on the data from the SYNERGY and A to Z trials, rather than details of anti-factor effects of heparins. We believe that this was well addressed in an overview of low-molecular-weight heparins by Weitz.¹

Pranab Das, MD; David J. Moliterno, MD
moliterno@uky.edu
Gill Heart Institute and Division of Cardiovascular Medicine
University of Kentucky
Lexington

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698. FREE FULL TEXT

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292:1427-1428.

RELATED ARTICLE

Fractionating Heparin
Ehud Arbit
JAMA. 2004;292(12):1427.
EXTRACT | FULL TEXT